The Dutch Ministry of Health (WVS) confirmed its intent to ban ashwagandha on April 10, 2026. The effective date has not yet been announced. Kerry Group launched its Safeguard Ashwagandha platform on May 11, 2026 at Vitafoods Europe, a publicly accessible industry initiative inviting all ingredient suppliers to contribute safety data to counter the regulatory bans. For supplement brands with Netherlands-based EU fulfillment or distribution, the Dutch ban intent is the most operationally significant ashwagandha development to date.

The Netherlands ban intent follows Denmark's existing national ban on leaf-derived ashwagandha, making the two countries in the EU's northwest logistics corridor the most restrictive jurisdictions for the ingredient. The Dutch ban reflects the Ministry of Health's concerns about withaferin-A concentrations and broader safety questions, concerns that Kerry Group and the wider industry argue are based on flawed risk assessment methodology from the Technical University of Denmark. Kerry's own Sensoril safety research, published April 27, 2026, demonstrated that the ingredient was safe at 4,000 mg/kg/day in animals, about 19 times the standard dose. The scientific dispute is ongoing, but the regulatory intent is confirmed.

For supplement brands with EU operations, the regulatory map now looks as follows. Denmark has a national ban on leaf-derived ashwagandha in force. The Netherlands confirmed intent to ban on April 10, 2026, with no effective date yet. France's ANSES has issued advisories against ashwagandha for specific populations. At EU level, an EFSA safety assessment was mandated in 2024, with the timeline not confirmed. In the UK, the FSA completed a call for evidence in September 2024 and the Committee on Toxicity assessment is ongoing. The regulatory direction across India, two EU member states, EFSA and the UK regulator is consistent. Brands relying on the current absence of an effective Netherlands ban date to defer action are carrying increasing market access risk.

• The Dutch Ministry of Health confirmed intent to ban ashwagandha on April 10, 2026, with no effective date yet, but it is now the planning assumption for Netherlands market access
• Kerry Group launched the Safeguard Ashwagandha platform on May 11, 2026, an open platform for safety data contribution to counter bans it argues rest on flawed risk assessment
• Kerry's Sensoril safety research (April 27, 2026) showed safety at 4,000 mg/kg/day, about 19 times the standard dose, in animal trials, though the regulatory process continues regardless
• Denmark ban (leaf-derived) in force, Netherlands intent confirmed April 10, France ANSES advisory in force, EFSA assessment ongoing, UK FSA assessment ongoing
• Supplement brands with Netherlands-based EU fulfillment must assess ashwagandha product viability now, not when an effective date is confirmed

The Netherlands ban intent changes the planning assumption for any supplement brand with ashwagandha products in its EU range. It does not require immediate product withdrawal, because the effective date is not confirmed. It does require an immediate assessment of which products are affected, what the Netherlands-specific market access risk looks like, and whether any formulation or sourcing changes are needed ahead of the effective date. Expandly includes EU supplement regulatory risk mapping, covering ingredient-level restrictions by member state, as part of EU market entry and ongoing compliance support.